Abstract:Maternal obesity is a global problem that increases the risk of short- and long-term adverse outcomes for mother and child, many of which are linked to gestational diabetes mellitus. Effective treatments are essential to prevent the transmission of poor metabolic health from mother to child. Metformin is an effective glucose lowering drug commonly used to treat gestational diabetes mellitus; however, its wider effects on maternal and fetal health are poorly explored. In this study we used a mouse (C57Bl6/J) model of diet-induced (high sugar/high fat) maternal obesity to explore the impact of metformin on maternal and feto-placental health. Metformin (300 mg kg-1 day-1 ) was given to obese females via the diet and was shown to achieve clinically relevant concentrations in maternal serum (1669 ± 568 nM in late pregnancy). Obese dams developed glucose intolerance during pregnancy and had reduced uterine artery compliance. Metformin treatment of obese dams improved maternal glucose tolerance, reduced maternal fat mass and restored uterine artery function. Placental efficiency was reduced in obese dams, with increased calcification and reduced labyrinthine area. Consequently, fetuses from obese dams weighed less (P < 0.001) at the end of gestation. Despite normalisation of maternal parameters, metformin did not correct placental structure or fetal growth restriction. Metformin levels were substantial in the placenta and fetal circulation (109.7 ± 125.4 nmol g-1 in the placenta and 2063 ± 2327 nM in fetal plasma). These findings reveal the distinct effects of metformin administration during pregnancy on mother and fetus and highlight the complex balance of risk vs. benefits that are weighed in obstetric medical treatments. KEY POINTS: Maternal obesity and gestational diabetes mellitus have detrimental short- and long-term effects for mother and child. Metformin is commonly used to treat gestational diabetes mellitus in many populations worldwide but the effects on fetus and placenta are unknown. In a mouse model of diet-induced obesity and glucose intolerance in pregnancy we show reduced uterine artery compliance, placental structural changes and reduced fetal growth. Metformin treatment improved maternal metabolic health and uterine artery compliance but did not rescue obesity-induced changes in the fetus or placenta. Metformin crossed the placenta into the fetal circulation and entered fetal tissue. Metformin has beneficial effects on maternal health beyond glycaemic control. However, despite improvements in maternal physiology, metformin did not prevent fetal growth restriction or placental ageing. The high uptake of metformin into the placental and fetal circulation highlights the potential for direct immediate effects of metformin on the fetus with possible long-term consequences postnatally.

Maternal diet modulates placental nutrient transporter gene expression in a mouse model of diabetic pregnancy

Nrf2 Signalling and Autophagy Are Involved in Diabetes Mellitus-Induced Defects in the Development of Mouse Placenta

Gestational diabetes mellitus impairs AKT-mTOR and SIRT1 signaling pathways in placenta

Poorly controlled diabetes mellitus alters placental structure, efficiency, and plasticity

Differential responses to maternal diabetes in embryo and visceral yolk sac

Diabetic Uterus Environment May Play a Key Role in Alterations of DNA Methylation of Several Imprinted Genes at Mid-Gestation in Mice

A combined in vivo and in silico model shows specific predictors of individual trans-generational diabetic programming

Gestational diabetes mellitus affects placental iron homeostasis: Mechanism and clinical implications

Gene expression profiles in placenta and their association with anesthesia, delivery mode and maternal diabetes

Maternal Dietary Glycaemic Change During Gestation Influences Insulin-Related Gene Methylation in the Placental Tissue: a Genome-Wide Methylation Analysis

Placental expression of GLUT‐1, GLUT‐3, and GLUT‐4 mRNA and transcriptome profiling in pregnant women with diabetes

Maternal Choline and Betaine Supplementation Modifies the Placental Response to Hyperglycemia in Mice and Human Trophoblasts

Obesogenic diet in pregnancy disrupts placental iron handling and ferroptosis and stress signalling in association with fetal growth alterations

Gestational Diabetes Mellitus Remodels the Fetal Brain Fatty Acid Profile Through Placenta-Brain Lipid Axis in C57BL/6J Mice

Maternal but not fetoplacental health can be improved by metformin in a murine diet-induced model of maternal obesity and glucose intolerance

The effect of high glucose on lipid metabolism in the human placenta

Epigenetic modifications of placenta in women with gestational diabetes mellitus and their offspring

Programming of cardiometabolic health: the role of maternal and fetal hyperinsulinaemia

Aberrant lipid accumulation in the mouse visceral yolk sac resulting from maternal diabetes and obesity

Prepregnancy maternal diabetes combined with obesity impairs placental mitochondrial function involving Nrf2/ARE pathway and detrimentally alters metabolism of offspring.

Metabolic Culprits in Obese Pregnancies and Gestational Diabetes Mellitus: Big Babies, Big Twists, Big Picture